Moderate to Severe Plaque Psoriasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Moderate to
Severe Plaque Psoriasis Market Outlook
Thelansis’s “Moderate
to Severe Plaque Psoriasis Market Outlook, Epidemiology, Competitive Landscape,
and Market Forecast Report – 2026 To 2036” covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Moderate
to Severe Plaque Psoriasis treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
Moderate to
Severe Plaque Psoriasis Overview
Moderate-to-severe plaque psoriasis is
a chronic, immune-mediated disorder characterized by keratinocyte
hyperproliferation and erythematous plaques with silvery scales. Driven by the
IL-23/Th17 axis, genetic susceptibility (notably HLA-Cw6), and environmental
triggers, it inflicts a heavy cardiometabolic and psychosocial burden. Because
a third of patients develop psoriatic arthritis, routine joint screening is
mandatory. While mild disease responds to topicals, moderate-to-severe
presentations require advanced systemic intervention, which has completely
evolved past standard step-up models. The biologic armamentarium has
dramatically expanded beyond single-cytokine blockers with the approval of
Bimzelx (bimekizumab), a first-in-class dual IL-17A and IL-17F inhibitor
delivering unprecedented complete skin clearance (PASI 100) rates. Crucially,
the oral treatment paradigm has been completely redefined. While the allosteric
TYK2 inhibitor Sotyktu (deucravacitinib) remains an option, it faces pressure
from the FDA approval of Icotyde (icotrokinra)—a groundbreaking, first-in-class
targeted oral peptide that directly blocks the IL-23 receptor to deliver
biologic-level efficacy in a daily pill. Paired with next-gen pipeline agents
like Takeda’s potent TYK2 inhibitor zasocitinib, modern management achieves
rapid, durable clearance while systematically minimizing long-term
cardiovascular risks.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment